Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 8;13:856186. doi: 10.3389/fimmu.2022.856186

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zhu, Huang, Liu, Peng, Xue, Feng, Huang, Chen, Lai, Ji, Wang and Yuan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

GILncSig predicts chemotherapy and immunotherapy response. (A–G) The signature showed high-risk scores were associated with a lower IC50 for chemotherapeutics such as (A) bortezomib, (B) gemcitabine, (C) imatinib, and (D) paclitaxel, whereas they were related to a higher IC50 for (E) axitinib, (F) docetaxel, and (G) lapatinib. (H) Differences in TIDE score between high- and low-risk groups. (I) Different expression of LINC00221 predicts response to anti-PD-1 immune checkpoint inhibition therapy in HCC patients. (J) Effects of with or without inhibition of LUCAT1 expression on PD-L1 protein expression levels by western blotting. **p<0.01,***p<0.001.